A comparative study of ddPCR and sanger sequencing for quantitative detection of low-frequency mutation rate
Author:
Open Access
- 1 October 2019
- conference paper
- Published by IOP Publishing in IOP Conference Series: Earth and Environmental Science
- Vol. 332 (3) , 032023
Abstract
Mutation detection has been applied to the entire diagnostic system of prevention, diagnosis, treatment, monitoring, and prognosis. However, owing to the limit of the technology, the low-frequency mutations are often identified as the false negative. Hence, this study focused on the comparison of Sanger sequencing and droplet digital PCR (ddPCR) in the quantitative detection of low-frequency mutation rate. The drug-induced deafness was chosen as the target for comparison, and the simulated samples and 15 clinical samples were detected respectively. The difference between the two methods was comprehensively analyzed in terms of repeatability, accuracy, dynamic detection range and concordance. The results showed that Sanger sequencing took advantage of acceptable cost, new mutations’ discovery, and high-throughput detection, while ddPCR performed better, especially in the detection of low-frequency mutations. In summary, this study compares in detail the merits and demerits of Sanger sequencing and ddPCR in the quantitative detection of low-frequency mutations, offering the potential to promote the further development of technology.Keywords
This publication has 18 references indexed in Scilit:
- A novel approach using long‐read sequencing and ddPCR to investigate gonadal mosaicism and estimate recurrence risk in two families with developmental disordersPrenatal Diagnosis, 2017
- Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancerCancer Letters, 2017
- Advances in Preimplantation Genetic Testing for Monogenic Disease and AneuploidyAnnual Review of Genomics and Human Genetics, 2017
- GeneticsObstetrics and Gynecology Clinics of North America, 2015
- Therapeutic Strategies Utilized in the Setting of Acquired Resistance to EGFR Tyrosine Kinase InhibitorsClinical Cancer Research, 2014
- Point mutations as a source of de novo genetic diseaseCurrent Opinion in Genetics & Development, 2013
- IDH1 mutation is sufficient to establish the glioma hypermethylator phenotypeNature, 2012
- Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancerNature Reviews Cancer, 2010
- The mutation rate and cancerProceedings of the National Academy of Sciences, 1996
- Biochemical evidence for nuclear gene involvement in phenotype of non- syndromic deafness associated with mitochondrial 12S rRNA mutationHuman Molecular Genetics, 1996